Vaccination campaign to contrast the spread of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has raised the issue of vaccine immunogenicity in special populations such as people with multiple sclerosis (PwMS) on highly effective disease modifying treatments (DMTs). While humoral responses to SARS-CoV-2 mRNA vaccines have been well characterized in the general population and in PwMS, very little is known about cell-mediated responses in conferring protection from SARS-CoV-2 infection and severe coronavirus disease-2019 (COVID-19).
Iannetta, M., Landi, D., Cola, G., Campogiani, L., Malagnino, V., Teti, E., et al. (2021). B- and T-Cell Responses After SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Receiving Disease Modifying Therapies: Immunological Patterns and Clinical Implications. FRONTIERS IN IMMUNOLOGY, 12, 796482 [10.3389/fimmu.2021.796482].
B- and T-Cell Responses After SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Receiving Disease Modifying Therapies: Immunological Patterns and Clinical Implications
Iannetta, Marco;Landi, Doriana;Malagnino, Vincenzo;Teti, Elisabetta;Buccisano, Francesco;Grelli, Sandro;Bernardini, Sergio;Andreoni, Massimo;Marfia, Girolama Alessandra;Sarmati, Loredana
2021-01-01
Abstract
Vaccination campaign to contrast the spread of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has raised the issue of vaccine immunogenicity in special populations such as people with multiple sclerosis (PwMS) on highly effective disease modifying treatments (DMTs). While humoral responses to SARS-CoV-2 mRNA vaccines have been well characterized in the general population and in PwMS, very little is known about cell-mediated responses in conferring protection from SARS-CoV-2 infection and severe coronavirus disease-2019 (COVID-19).File | Dimensione | Formato | |
---|---|---|---|
B- and T-Cell Responses After SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Receiving Disease Modifying Therapies Immunological Patterns and Clinical Implications.pdf
solo utenti autorizzati
Licenza:
Non specificato
Dimensione
5.52 MB
Formato
Adobe PDF
|
5.52 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.